Kojin Therapeutics
Boston, US · Founded 2019 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
NM
Nagesh Mahanthappa, Ph.D.Named on SEC filing
LG
Luba GreenwoodNamed on SEC filing
Board
AN
Amir Nashat, Ph.D.Treasurer and Secretary
SL
Susan LangerPresident
TJ
Investors · 1
Reported raises · per SEC filings
Form D private placements$30.2M disclosed across 1 round · 2021
▶$30.2MraisedJun 2021 · 14 investors · BiotechnologyRule 506(b)
▶$30.2MraisedJun 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nagesh Mahanthappa, Ph.D.Director
- Amir Nashat, Ph.D.Executive Officer, Director
- Susan LangerExecutive Officer
- Luba GreenwoodDirector
- Thomas J. CahillDirector
- Offering amount
- $60.2M
- Amount sold
- $30.2M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Kojin Therapeutics's investors?
- Kojin Therapeutics's investors include Newpath Partners.
- How much funding has Kojin Therapeutics raised?
- Kojin Therapeutics has disclosed $30.2M raised across 1 round.
- Where is Kojin Therapeutics headquartered?
- Kojin Therapeutics is headquartered in Boston, US.